ADMA Biologics Inc (ADMA)
6.735
+0.06
(+0.97%)
USD |
NASDAQ |
May 02, 16:00
6.735
0.00 (0.00%)
After-Hours: 18:57
ADMA Biologics Enterprise Value: 1.601B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 1.601B |
| April 30, 2024 | 1.567B |
| April 29, 2024 | 1.581B |
| April 26, 2024 | 1.574B |
| April 25, 2024 | 1.549B |
| April 24, 2024 | 1.554B |
| April 23, 2024 | 1.572B |
| April 22, 2024 | 1.494B |
| April 19, 2024 | 1.510B |
| April 18, 2024 | 1.494B |
| April 17, 2024 | 1.458B |
| April 16, 2024 | 1.485B |
| April 15, 2024 | 1.444B |
| April 12, 2024 | 1.453B |
| April 11, 2024 | 1.499B |
| April 10, 2024 | 1.458B |
| April 09, 2024 | 1.474B |
| April 08, 2024 | 1.499B |
| April 05, 2024 | 1.538B |
| April 04, 2024 | 1.512B |
| April 03, 2024 | 1.528B |
| April 02, 2024 | 1.549B |
| April 01, 2024 | 1.572B |
| March 28, 2024 | 1.585B |
| March 27, 2024 | 1.617B |
| Date | Value |
|---|---|
| March 26, 2024 | 1.563B |
| March 25, 2024 | 1.538B |
| March 22, 2024 | 1.515B |
| March 21, 2024 | 1.492B |
| March 20, 2024 | 1.522B |
| March 19, 2024 | 1.492B |
| March 18, 2024 | 1.435B |
| March 15, 2024 | 1.446B |
| March 14, 2024 | 1.453B |
| March 13, 2024 | 1.508B |
| March 12, 2024 | 1.499B |
| March 11, 2024 | 1.490B |
| March 08, 2024 | 1.526B |
| March 07, 2024 | 1.485B |
| March 06, 2024 | 1.476B |
| March 05, 2024 | 1.403B |
| March 04, 2024 | 1.385B |
| March 01, 2024 | 1.339B |
| February 29, 2024 | 1.303B |
| February 28, 2024 | 1.307B |
| February 27, 2024 | 1.339B |
| February 26, 2024 | 1.312B |
| February 23, 2024 | 1.280B |
| February 22, 2024 | 1.268B |
| February 21, 2024 | 1.250B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
185.96M
Minimum
Mar 18 2020
1.617B
Maximum
Mar 27 2024
517.23M
Average
324.30M
Median
Oct 26 2021
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -113.81M |
| ANI Pharmaceuticals Inc | 1.489B |
| Ligand Pharmaceuticals Inc | 1.095B |
| Puma Biotechnology Inc | 241.62M |
| Bristol-Myers Squibb Co | 135.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.64M |
| Revenue (Quarterly) | 73.90M |
| Total Expenses (Quarterly) | 59.67M |
| EPS Diluted (Quarterly) | -0.08 |
| Gross Profit Margin (Quarterly) | 42.06% |
| Profit Margin (Quarterly) | -23.88% |
| Earnings Yield | -1.93% |
| Operating Earnings Yield | 1.43% |
| Normalized Earnings Yield | -0.2105 |